RVA576 ( DrugBank: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
62	発作性夜間ヘモグロビン尿症	9
109	非典型溶血性尿毒症症候群	5
162	類天疱瘡（後天性表皮水疱症を含む。）	6

62. 発作性夜間ヘモグロビン尿症

臨床試験数 : 292 / 薬物数 : 151 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 108

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004129-18-LT (EUCTR)	15/03/2019	29/01/2019	An extension study on rVA576(Coversin) for Patients with PNH and aHUS who received benefit from thei ...	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: COVERSIN	Akari Therapeutics Plc	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom;India
2	NCT03588026 (ClinicalTrials.gov)	June 7, 2018	1/6/2018	Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576	Investigational Product ; Coversin. Phase III Safety and Efficacy in Three-Part, Two-Arm, Randomised ...	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Drug: rVA576;Other: Standard of care (SOC)	AKARI Therapeutics	NULL	Completed	18 Years	N/A	All	9	Phase 3	Kazakhstan;Lithuania;Sri Lanka
3	EUCTR2017-003847-39-LT (EUCTR)	12/03/2018	23/01/2018	A study to assess the safety and efficacy of rVA576in patients with Paroxysmal Nocturnal Haemoglobin ...	CAPSTONE: Phase III Confirmatory Assessment Protocol: rVA576Safety and Efficacy in Three-Part, Two-A ...	Paroxysmal Nocturnal Haemoglobinuria (PNH) MedDRA version: 21.1;Level: PT;Classification code 100340 ...	Product Code: rVA576 INN or Proposed INN: NA	Akari Therapeutics Plc.	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 3	Ecuador;Romania;Turkey;Lithuania;Peru;Kazakhstan;Sri Lanka
4	EUCTR2016-004129-18-NL (EUCTR)	14/02/2018	16/11/2017	An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initia ...	CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Name: Coversin Product Code: rVA576 INN or Proposed INN: COVERSIN Other descriptive name: COVER ...	Akari Therapeutics Plc	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	Argentina;Poland;Lithuania;Netherlands;United Kingdom
5	EUCTR2016-004129-18-GB (EUCTR)	17/03/2017	21/12/2016	An extension study on rVA576(Coversin) for Patients with PNH and aHUS who received benefit from thei ...	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: rVA576	Akari Therapeutics Plc	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom
6	NCT03829449 (ClinicalTrials.gov)	March 13, 2017	20/12/2018	rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal Nocturnal Hemoglobinuria	Drug: rVA576 (Coversin)	AKARI Therapeutics	NULL	Terminated	18 Years	N/A	All	15	Phase 3	Poland
7	EUCTR2016-004129-18-PL (EUCTR)	07/03/2017	18/01/2017	An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initia ...	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Name: rVA576(Coversin) Product Code: rVA576 INN or Proposed INN: rVA576(COVERSIN) Other descrip ...	Akari Therapeutics Plc	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 3	France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom
8	EUCTR2016-002067-33-GB (EUCTR)	18/07/2016	16/08/2016	An Open Clincal Trial of Coversin in Patients with PNH	COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients	Paroxysmal nocturnal haemoglobinuria (PNH) MedDRA version: 20.0;Level: PT;Classification code 100340 ...	Product Name: Coversin Product Code: rVA576 INN or Proposed INN: COVERSIN Other descriptive name: COVER ...	Akari Therapeutics Plc	NULL	Not Recruiting			Female: yes Male: yes	10	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom
9	EUCTR2015-003778-34-NL (EUCTR)	13/01/2016	10/12/2015	Coversin in Paroxysmal Nocturnal Haemoglobulinuria (PNH) in patients with resistance to Eculizumab d ...	Coversin in Paroxysmal Nocturnal Haemoglobulinuria (PNH) in patients with resistance to Eculizumab d ...	Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due ...	Product Name: Coversin Product Code: rVA576 INN or Proposed INN: Not applicable Other descriptive name: ...	Volution Immuno Pharmaceuticals (UK) Ltd	NULL	Not Recruiting			Female: yes Male: yes	6	Phase 2	Netherlands

First Previous1Next Last

先頭へ

109. 非典型溶血性尿毒症症候群

臨床試験数 : 114 / 薬物数 : 36 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004129-18-LT (EUCTR)	15/03/2019	29/01/2019	An extension study on rVA576(Coversin) for Patients with PNH and aHUS who received benefit from thei ...	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: COVERSIN	Akari Therapeutics Plc	NULL	Not Recruiting	Female: yes Male: yes	50	Phase 3	France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom;India
2	EUCTR2016-004129-18-NL (EUCTR)	14/02/2018	16/11/2017	An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initia ...	CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Name: Coversin Product Code: rVA576 INN or Proposed INN: COVERSIN Other descriptive name: COVER ...	Akari Therapeutics Plc	NULL	Not Recruiting	Female: yes Male: yes	50	Phase 3	Argentina;Poland;Lithuania;Netherlands;United Kingdom
3	EUCTR2017-000064-15-GB (EUCTR)	14/09/2017	28/06/2017	A study of Safety and Efficacy of Coversin in adult aHUS subjects	A Phase 2, single arm study of Safety and Efficacy of Coversin in adult aHUS subjects	Atypical haemolytic uraemic syndrome (aHUS) MedDRA version: 20.0;Level: PT;Classification code 10018 ...	Product Name: Coversin Product Code: rVA576 INN or Proposed INN: Coversin Other descriptive name: COVER ...	Akari Therapeutics Plc	,NULL	Not Recruiting	Female: yes Male: yes	10	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United Kingdom
4	EUCTR2016-004129-18-GB (EUCTR)	17/03/2017	21/12/2016	An extension study on rVA576(Coversin) for Patients with PNH and aHUS who received benefit from thei ...	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Code: rVA576 INN or Proposed INN: rVA576 Other descriptive name: rVA576	Akari Therapeutics Plc	NULL	Not Recruiting	Female: yes Male: yes	50	Phase 3	France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom
5	EUCTR2016-004129-18-PL (EUCTR)	07/03/2017	18/01/2017	An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initia ...	CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study	Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) MedDRA ve ...	Product Name: rVA576(Coversin) Product Code: rVA576 INN or Proposed INN: rVA576(COVERSIN) Other descrip ...	Akari Therapeutics Plc	NULL	Not Recruiting	Female: yes Male: yes	50	Phase 3	France;Argentina;Poland;Lithuania;Kazakhstan;Netherlands;Germany;Sri Lanka;United Kingdom

First Previous1Next Last

先頭へ

162. 類天疱瘡（後天性表皮水疱症を含む。）

臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05061771 (ClinicalTrials.gov)	May 6, 2022	15/9/2021	Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Th ...	A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical ...	Bullous Pemphigoid	Drug: nomacopan (rVA576);Other: Placebo	AKARI Therapeutics	NULL	Withdrawn	18 Years	99 Years	All	0	Phase 3	United States;Germany;Netherlands;Poland
2	EUCTR2020-005987-67-NL (EUCTR)	22/04/2022	24/11/2021	A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bull ...	A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical ...	moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;T ...	Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA ...	Akari Therapeutics Plc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	United States;Germany;Netherlands
3	EUCTR2020-005987-67-DE (EUCTR)	22/12/2021	16/07/2021	A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bull ...	A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical ...	moderate to severe bullous pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;T ...	Product Name: nomacopan Product Code: rVA576 INN or Proposed INN: NOMACOPAN Other descriptive name: rVA ...	Akari Therapeutics Plc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	United States;Germany
4	NCT04035733 (ClinicalTrials.gov)	September 25, 2018	12/4/2019	rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects	A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576in Adult Mild to Moderate Bu ...	Bullous Pemphigoid (BP)	Drug: rVA576	AKARI Therapeutics	NULL	Completed	18 Years	N/A	All	9	Phase 2	Germany;Netherlands
5	EUCTR2017-002836-18-DE (EUCTR)	23/07/2018	14/02/2018	A Clinical study to investigate if rVA576is safe and has an effect on patients who have mild or mode ...	A Phase IIa open label single arm study of safety and efficacy of rVA576in adult mild to moderate Bu ...	Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Ter ...	Product Name: rVA576 INN or Proposed INN: rVA576	Akari Therapeutics Plc.	NULL	Not Recruiting			Female: yes Male: yes	9	Phase 2	Netherlands;Germany
6	EUCTR2017-002836-18-NL (EUCTR)	07/05/2018	24/01/2018	A Clinical study to investigate if rVA576is safe and has an effect on patients who have mild or mode ...	A Phase IIa open label single arm study of safety and efficacy of rVA576in adult mild to moderate Bu ...	Mild to Moderate Bullous Pemphigoid MedDRA version: 21.1;Level: LLT;Classification code 10006567;Ter ...	Product Name: rVA576 INN or Proposed INN: rVA576	Akari Therapeutics Plc.	NULL	Not Recruiting			Female: yes Male: yes	9	Phase 2	Germany;Netherlands

First Previous1Next Last

先頭へ